Search

Your search keyword '"Torrente-Segarra, Vicenç"' showing total 204 results
Start Over Author "Torrente-Segarra, Vicenç"
204 results on '"Torrente-Segarra, Vicenç"'

1. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

Author

Laíño-Piñeiro, María-Cruz, Rúa-Figueroa, Iñigo, Jiménez, Norman, Lozano, María José Cuadrado, Martínez-Barrio, Julia, Serrano, Belén, Galindo-Izquierdo, María, Nack, Annika, Loricera, Javier, Tomero-Muriel, Eva, Ibáñez-Barceló, Mónica, Vázquez, Natalia Mena, Manrique-Arija, Sara, Lorenzo, Nerea Alcorta, Narváez, Javier, Rosas, José, Menor-Almagro, Raúl, Martínez-Taboada, Víctor Manuel, Aurrecoechea-Aguinaga, Elena, Horcada, Loreto, Ruiz-Lucea, Esther, Raya, Enrique, Toyos, F Javier, Expósito, Lorena, Vela, Paloma, Freire-González, Mercedes, Moriano-Morales, Clara, Bonilla-Hernán, Gema, Ibáñez, Tatiana Cobo, Lozano-Rivas, Nuria, Moreno, Mireia, Andreu, José Luis, Ubiaga, Carlota Laura Iniguez, Torrente-Segarra, Vicenç, Valls, Elia, Velloso-Feijoo, M.L., Alcázar, Juan Luis, and Pego-Reigosa, José M

Published
2023
Full Text
View/download PDF

3. Juvenile idiopathic arthritis in the young adult. Methodology, objectives, and initial data from the JUVENSER registry

Author

Bethencourt-Baute, Juan José, Montero, Nuria, Zacarias, Andrea M., Nieto, Juan Carlos, López-Corbeto, Mireia, Boteanu, Alina, Medrano, Marta, Díaz-Cordovés Rego, Gisela, Vargas-Lebron, Carmen, Machín-García, Sergio, Expósito, Lorena, Cacheda, Ana Paula, Bernabeu, Pilar, Veroz-González, Raúl, Fernández, Olaia, Enriquez Merayo, Eugenia, Torrente-Segarra, Vicenç, Fernández-Alba, María Dolores, Gamir, María Luz, López-Robledillo, Juan Carlos, Antón, Jordi, Otero, Lucía, and Bustabad, Sagrario

Published
2023
Full Text
View/download PDF

4. Artritis idiopática juvenil en el adulto joven. Metodología, objetivos y datos iniciales del registro JUVENSER

Author

Bethencourt-Baute, Juan José, Montero, Nuria, Zacarias, Andrea M., Nieto, Juan Carlos, López-Corbeto, Mireia, Boteanu, Alina, Medrano, Marta, Díaz-Cordovés Rego, Gisela, Vargas-Lebron, Carmen, Machín-García, Sergio, Expósito, Lorena, Cacheda, Ana Paula, Bernabeu, Pilar, Veroz-González, Raúl, Fernández, Olaia, Enriquez Merayo, Eugenia, Torrente-Segarra, Vicenç, Fernández-Alba, María Dolores, Gamir, María Luz, López-Robledillo, Juan Carlos, Antón, Jordi, Otero, Lucía, and Bustabad, Sagrario

Published
2023
Full Text
View/download PDF

5. Clinical outcomes of switching to adalimumab biosimilar (MSB11022) in patients with rheumatoid arthritis: RESTART Spanish Registry.

Author

García-Miguel, Javier, Yankova Komsalova, Liliya, Mata Arnaiz, Cristina, Alegre-Sancho, Juan José, González Polo, Javier, Torrente-Segarra, Vicenç, Tornero Molina, Jesús, Navarro Angeles, Vanessa Andrea, Caramés, Cristina, and Cristóbal, Ion

Subjects
BIOTHERAPY, RHEUMATOID arthritis, IMMUNE response, MEDICAL records, BIOSIMILARS
Abstract

MSB11022 is a biosimilar of adalimumab that has been shown comparable bioequivalence, safety, tolerability, and immunogenicity profiles to the reference adalimumab in healthy volunteers or in patients with psoriasis or rheumatoid arthritis (RA). This is the first study conducted under clinical practice conditions evaluating the switch from reference adalimumab to MSB11022 in patients with RA. Retrospective and multicenter study with data from the medical records of patients with RA who switched from reference adalimumab or another biosimilar to MSB11022 and maintained this treatment for at least 6 months. Information registered comes from baseline visit, the moment of the switch, and the follow-up visits. Data from 86 patients were evaluated (median age 63.5 years, 75.6% female, 44.2% had erosive RA). Only 3.5% of the patients received biologic therapy prior to adalimumab. At baseline, median DAS28-CRP was 1.77 (80.2% in remission and 96.5% with low disease activity) and median CDAI was 4.00 (44.2% in remission and 90.7% with low disease activity). After a median follow-up of 8 months, median DAS28-CRP was 1.87 (86.0% in remission and 94.2% with low disease activity) and median CDAI was 4.00 (38.5% in remission and 95.3% with low disease activity). Only three patients experienced pain, swelling, and stinging at the injection site or a locally extensive hematoma in the area of administration. Adalimumab biosimilar MSB11022 maintained the efficacy benefits provided by previous adalimumab treatments with a safety profile in line with that already described for other biosimilars. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome

Author

Salman-Monte, Tarek Carlos, Sanchez-Piedra, Carlos, Fernandez Castro, Monica, Andreu, Jose Luis, Martinez Taboada, Victor, Olivé, Alejandro, Rosas, José, Menor, Raúl, Rodríguez, Beatriz, Garcia Aparicio, Angel, Lopez Longo, Francisco Javier, Manrique-Arija, Sara, Garcia Vadillo, Jesus Alberto, Gil Barato, Susana, López-González, Ruth, Galisteo, Carlos, Gonzalez Martin, Jorge, Ruiz Lucea, Esther, Erausquin, Celia, Melchor, Sheila, Moreira, Begoña, Raya, Enrique, Pego-Reigosa, Jose María, Cid, Natalia, Júdez, Enrique, Moriano, Clara, Narváez, Francisco Javier, Corominas, Hèctor, Garcia Magallon, Blanca, Guillen Astete, Carlos, Castellvi, Ivan, Bohórquez, Cristina, Loricera, Javier, Belzunegui, Joaquín, Illera, Óscar, and Torrente-Segarra, Vicenç

Published
2020
Full Text
View/download PDF

10. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

Author

Queiro, Rubén, Laiz, Ana, Seoane-Mato, Daniel, Galindez Agirregoikoa, Eva, Montilla, Carlos, Park, Hye Sang, Bethencourt Baute, Juan José, Bustabad, Sagrario, Pinto Tasende, Jose A., Tejón, Patricia, Joven Ibáñez, Beatriz, Ramírez, Julio, Cuervo, Andrea, Cañete, Juan D., Trenor Larraz, Pilar, Ordás, Carmen, Alonso, Sara, García-Fernández, Edilia, Toniolo, Elide, Moreno Ramos, Manuel José, Beteta, María Dolores, Lojo Oliveira, Leticia, Navío Marco, Teresa, Cebrián, Laura, Barbazán, Ceferino, Maceiras, Francisco, Rodriguez-Moreno, Jesús, Steiner, Martina, Muñoz-Fernández, Santiago, Nóvoa Medina, Francisco Javier, León, Manuel, Rubio, Esteban, Medina Luezas, Julio, Sánchez-González, María Dolores, Arévalo, Marta, Gratacós, Jordi, Senabre, José Miguel, Rosas, José Carlos, Santos Soler, Gregorio, Nieto-González, Juan Carlos, González, Carlos, López Robles, Alejandra, Álvarez Castro, Carolina, Ruiz Montesino, María Dolores, Torrente-Segarra, Vicenç, Fernández-Carballido, Cristina, Martínez-Vidal, María Paz, Jovani, Vega, Urruticoechea-Arana, Ana, Cabello Fernández, Yolanda, Toledo, María Dolores, Almodóvar, Raquel, Belmonte-Serrano, Miguel Ángel, Notario Ferreira, Irene, and Raya Álvarez, Enrique

Published
2019
Full Text
View/download PDF

11. Registro Español de Artritis Psoriásica de Reciente Comienzo (estudio REAPSER). Objetivos y metodología

Author

Queiro, Rubén, Laiz, Ana, Seoane-Mato, Daniel, Galindez Agirregoikoa, Eva, Montilla, Carlos, Park, Hye Sang, Bethencourt Baute, Juan José, Bustabad, Sagrario, Pinto Tasende, Jose A., Tejón, Patricia, Joven Ibáñez, Beatriz, Ramírez, Julio, Cuervo, Andrea, Cañete, Juan D., Trenor Larraz, Pilar, Ordás, Carmen, Alonso, Sara, García-Fernández, Edilia, Toniolo, Elide, Moreno Ramos, Manuel José, Beteta, María Dolores, Lojo Oliveira, Leticia, Navío Marco, Teresa, Cebrián, Laura, Barbazán, Ceferino, Maceiras, Francisco, Rodriguez-Moreno, Jesús, Steiner, Martina, Muñoz-Fernández, Santiago, Nóvoa Medina, Francisco Javier, León, Manuel, Rubio, Esteban, Medina Luezas, Julio, Sánchez-González, María Dolores, Arévalo, Marta, Gratacós, Jordi, Senabre, José Miguel, Rosas, José Carlos, Santos Soler, Gregorio, Nieto-González, Juan Carlos, González, Carlos, López Robles, Alejandra, Álvarez Castro, Carolina, Ruiz Montesino, María Dolores, Torrente-Segarra, Vicenç, Fernández-Carballido, Cristina, Martínez-Vidal, María Paz, Jovani, Vega, Urruticoechea-Arana, Ana, Cabello Fernández, Yolanda, Toledo, María Dolores, Almodóvar, Raquel, Belmonte-Serrano, Miguel Ángel, Notario Ferreira, Irene, and Raya Álvarez, Enrique

Published
2019
Full Text
View/download PDF

12. LP-171 Fibromyalgia and glucocorticoids use drives self-perceived depression in systemic lupus erythematosus: insights from a large prospective and multicenter study using Relesserpros register’s database.

Author

Rúa-Figueroa, Iñigo, primary, Martínez-Barrio, Julia, additional, Jiménez, Norman, additional, Galindo-Izquierdo, María, additional, Uriarte-Isacelaya, Esther, additional, Fernandez-Nebro, Antonio, additional, Calvo, Jaime, additional, Manrique-Arija, Sara, additional, Rosas, Jose, additional, Caño-Alameda, Rocio, additional, Narváez, J., additional, Ros, Inmaculada, additional, Aurrecoechea, Elena, additional, Torrente-Segarra, Vicenç, additional, Sanguesa, Clara, additional, Freire-González, Mercedes, additional, Tomero-Muriel, Eva, additional, Horcada, Loreto, additional, Moriano, Clara, additional, Moreno, Mireia, additional, Laura-Iñíguez, Carlota, additional, Blanco, Ricardo, additional, Pérez-Gómez, Ana, additional, Andréu-Sánchez, José Luis, additional, Garrote-Corral, Sandra, additional, Muñoz-Fernández, Santiago, additional, Bonilla, Gema, additional, Lozano-Rivas, Nuria, additional, Montilla-Morales, Carlos A, additional, Ibarguengoitia, O, additional, Expósito, Lorena, additional, Vals-Pascual, Elia, additional, Pecondon-Español, Angela, additional, Machín, Sergio, additional, Salgado-Perez, Eva, additional, Celia-Erausquin, Maria, additional, Salman-Monte, Tarek Carlos, additional, Menor-Almagro, Raúl, additional, Muñoz-Jimenez, Alejandro, additional, Altabás-González, Irene, additional, Fragío-Gil, Jorge Juan, additional, and Pego-Reigosa, Jose María, additional

Published
2023
Full Text
View/download PDF

14. Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study

Author

Corominas, Héctor, Alegre, Cayetano, Narváez, Javier, Fernández-Cid, Carlos Marras, Torrente-Segarra, Vicenç, Gómez, Manuel Rodríguez, Pan, Francisco Maceiras, Morlà, Rosa María, Martínez, Fernando José Rodríguez, Gómez-Centeno, Antoni, Ares, Laura Losada, Molina, Rocío González, González-Albo, Silvia Paredes, Dalmau-Carolà, Joan, Pérez-García, Carolina, Álvarez, Ceferino Barbazán, Ercole, Liliana, and Terrancle, Maria Ángeles

Published
2019
Full Text
View/download PDF

17. Nailfold capillaroscopic findings in primary Sjögren’s syndrome with and without Raynaud’s phenomenon and/or positive anti-SSA/Ro and anti-SSB/La antibodies

Author

Corominas, Hèctor, Ortiz-Santamaría, Vera, Castellví, Iván, Moreno, Mireia, Morlà, Rosa, Clavaguera, Teresa, Erra, Alba, Martínez-Pardo, Silvia, Ordóñez, Sergi, Santo, Pilar, Reyner, Patricia, González, Maria José, Codina, Oriol, Gelman, Mario Saul, Juanola-Roura, Xavier, Olivé, Alex, Torrente-Segarra, Vicenç, and CapiCAT group

Published
2016
Full Text
View/download PDF

18. Consensus of the Spanish society of pediatric rheumatology for transition management from pediatric to adult care in rheumatic patients with childhood onset

Author

Calvo, Inmaculada, Antón, Jordi, Bustabad, Sagrario, Camacho, Marisol, de Inocencio, Jaime, Gamir, Mª Luz, Graña, Jenaro, La Cruz, Lucía, Robledillo, Juan Carlos López, Medrano, Marta, Merino, Rosa, Modesto, Consuelo, Nuñez, Esmeralda, Rua, Mª Jesús, Torrente-Segarra, Vicenç, Vargas, Carmen, Carmona, Loreto, and Loza, Estíbaliz

Published
2015
Full Text
View/download PDF

26. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER)

Author

Torrente-Segarra, Vicenç, Salman-Monte, Tarek C, Rúa-Figueroa, Íñigo, Del Campo, Víctor, López-Longo, Francisco Javier, Galindo-Izquierdo, María, Calvo-Alén, Jaime, Olivé-Marqués, Alejandro, Mouriño-Rodríguez, Coral, Horcada, Loreto, Bohórquez, Cristina, Montilla, Carlos, Salgado, Eva, Díez-Álvarez, Elvira, Blanco, Ricardo, Andreu, José Luis, Fernández-Berrizbeitia, Olaia, Expósito, Lorena, Gantes, Marian, Hernández-Cruz, Blanca, Pecondón-Español, Ángela, Lozano-Rivas, Nuria, Bonilla, Gema, Lois Iglesias, Ana, Rubio-Muñoz, Paula, Ovalles, Juan, Tomero, Eva, Boteanu, Alina, Narvaez, Javier, Freire, Mercedes, Vela, Paloma, Quevedo-Vila, Víctor, Juan Mas, Antonio, Muñoz-Fernández, Santiago, Raya, Enrique, Moreno, Mireia, Velloso-Feijoo, M L, Soler, Gregorio, Vázquez-Rodríguez, Tomás Ramón, Pego-Reigosa, José M, and RELESSER Study Group of the Spanish Society of Rheumatology (SER) and the Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER)

Subjects
Adult, Male, RELESSER, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Splenectomy, Serious infection, Infections, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Adrenal Cortex Hormones, Internal medicine, medicine, Humans, Lupus Erythematosus, Systemic, Registries, 030212 general & internal medicine, Serious Infections, Child, skin and connective tissue diseases, Retrospective Studies, 030203 arthritis & rheumatology, Juvenile-onset Systemic Lupus Erythematosus, Systemic lupus erythematosus, business.industry, Incidence, Incidence (epidemiology), Retrospective cohort study, medicine.disease, 3. Good health, Large cohort, Cross-Sectional Studies, Anesthesiology and Pain Medicine, Juvenile onset, Female, business, Immunosuppressive Agents, Follow-Up Studies
Abstract

Objective: To assess the incidence of serious infection (SI) and associated factors in a large juvenile-onset systemic lupus erythematosus (jSLE) retrospective cohort. Methods: All patients in the Spanish Rheumatology Society Lupus Registry (RELESSER) who meet >= 4 ACR-97 SLE criteria and disease onset = 6, 5.8%). Incidence rate was 3.7 (95%CI: 3.2-4.2) SI per 100 patient years. Respiratory location and bacterial infections were the most frequent. Higher number of SLE classification criteria, SLICC/ACR DI score and immunosuppressants use were associated to the presence of SI. Associated factors to shorter time to first infection were higher number of SLE criteria, splenectomy and immunosuppressants use. Conclusions: The risk of SI in jSLE patients is significant and higher than aSLE. It is associated to higher number of SLE criteria, damage accrual, some immunosuppressants and splenectomy. (C) 2020 Elsevier Inc. All rights reserved.

Published
2020

30. Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases : Results of the Cardiovascular in Rheumatology (Carma) Project

Author

Valero-Jaimes, Jesús A., López-González, Ruth, Martín-Martínez, María A., García-Gómez, Carmen, Sánchez-Alonso, Fernando, Sánchez-Costa, Jesús T., González Juanatey, Carlos, Revuelta-Evrad, Eva, Díaz-Torné, César, Fernández-Espartero, Cruz, Pérez-García, Carolina, Torrente Segarra, Vicenç, Sánchez-Nievas, Ginés, Pérez-Sandoval, Trinidad, Font-Ugalde, Pilar, García-Vivar, María Luz, Aurrecoechea, Elena, Maiz-Alonso, Olga, Valls-García, Ramón, Miranda-Filloy, José A., Llorca Díaz, Javier, Castañeda, Santos, González-Gay, Miguel A., CARMA Study Group, Nolla Solé, Joan Miquel, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP), and Universidad de Cantabria

Subjects
medicine.medical_specialty, Medicina, lcsh:Medicine, 030204 cardiovascular system & hematology, Article, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Internal medicine, medicine, Rheumatoid factor, Obesity, Rheumatoid arthritis, BASDAI, Rheumatism, Body mass index, Psoriatic arthritis and disease activity, Inflammation, 030203 arthritis & rheumatology, Ankylosing spondylitis, business.industry, Reumatisme, lcsh:R, Enthesitis, General Medicine, medicine.disease, Inflamació, Rheumatology, Obesitat, medicine.symptom, business
Abstract

Objective: Since obesity has been associated with a higher inflammatory burden and worse response to therapy in patients with chronic inflammatory rheumatic diseases (CIRD), we aimed to confirm the potential association between body mass index (BMI) and disease activity in a large series of patients with CIRDs included in the Spanish CARdiovascular in rheuMAtology (CARMA) registry. Methods: Baseline data analysis of patients included from the CARMA project, a 10-year prospective study of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) attending outpatient rheumatology clinics from 67 Spanish hospitals. Obesity was defined when BMI (kg/m2) was &gt, 30 according to the WHO criteria. Scores used to evaluate disease activity were Disease Activity Score of 28 joints (DAS28) in RA, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS, and modified DAS for PsA. Results: Data from 2234 patients (775 RA, 738 AS, and 721 PsA) were assessed. The mean &plusmn, SD BMI at the baseline visit were: 26.9 &plusmn, 4.8 in RA, 27.4 &plusmn, 4.4 in AS, and 28.2 &plusmn, 4.7 in PsA. A positive association between BMI and disease activity in patients with RA (&beta, = 0.029, 95%CI (0.01&ndash, 0.05), p = 0.007) and PsA (&beta, = 0.036, 95%CI (0.015&ndash, 0.058), p = 0.001) but not in those with AS (&beta, = 0.001, 95%CI (&minus, 0.03&ndash, 0.03), p = 0.926) was found. Disease activity was associated with female sex and rheumatoid factor in RA and with Psoriasis Area Severity Index and enthesitis in PsA. Conclusions: BMI is associated with disease activity in RA and PsA, but not in AS. Given that obesity is a potentially modifiable factor, adequate control of body weight can improve the outcome of patients with CIRD and, therefore, weight control should be included in the management strategy of these patients.

Published
2021

35. A comparative study on clinical and serological characteristics between patients with rhupus and those with systemic lupus erythematosus and rheumatoid arthritis

Author

Frade-Sosa, Beatriz, primary, Narváez, Javier, additional, Salman-Monte, Tarek Carlos, additional, Castellanos-Moreira, Raul, additional, Ortiz-Santamaria, Vera, additional, Torrente-Segarra, Vicenç, additional, Castellvi, Ivan, additional, Magallares, Berta, additional, Reina, Delia, additional, Minguez, Sonia, additional, Sallés, Meritxell, additional, Manrique de Lara, Maria García, additional, Ordoñez, Sergi, additional, Riera, Elena, additional, Schur, Peter H, additional, and Gómez-Puerta, José A, additional

Published
2020
Full Text
View/download PDF

38. 181 Associated factors to the presence of serious infections in a large cohort of juvenile-onset systemic lupus erythematosus

Author

Maria Pego Reigosa, Jose, primary, Torrente-Segarra, Vicenç, additional, Perez, Victor Del Campo, additional, Salman-Monte, Tarek, additional, Narváez-García, Javier, additional, López-Longo, Francisco Javier, additional, Ovalles, Juan, additional, Rubio, Paula, additional, Izquierdo, Maria Galindo, additional, Andréu-Sánchez, José L, additional, Alen, Jaime Calvo, additional, Uriarte, Esther, additional, Tomero-Muriel, EvaG, additional, Pecondón-Español, Ángela, additional, Freire-González, Mercedes, additional, Taboada, Victor Martínez, additional, Moreno-Martínez-Losa, Mireia, additional, Ibáñez-Barcelo, Mónica, additional, Lois-Iglesias, Ana, additional, Sánchez-Atrio, Ana, additional, Horcada, Loreto, additional, and Rua-Figueroa, Iñigo, additional

Published
2019
Full Text
View/download PDF

40. The Challenges of Diagnosing Cognitive Dysfunction with Neuropsychiatric Systemic Lupus Erythematosus in Childhood

Author

AlE’ed, Ashwaq, Vega-Fernandez, Patricia, Muscal, Eyal, Hinze, Claas, Tucker, Lori B., Appenzeller, Simone, Bader-Meunier, Brigitte, Roth, Johannes, Torrente-Segarra, Vicenç, Klein-Gitelman, Marisa S, Levy, Deborah M, Roebuck-Spencer, Tresa, and Brunner, Hermine

Subjects
Adolescent, Lupus Vasculitis, Central Nervous System, Child Behavior, Neuroimaging, Neuropsychological Tests, Article, Cognition, Adolescent Behavior, Predictive Value of Tests, Risk Factors, Child, Preschool, Humans, Age of Onset, Child, Cognition Disorders
Abstract

The diagnosis of Neuropsychiatric systemic lupus erythematosus disease (NPSLE) is challenging. The Automated Neuropsychological Assessment Metrics (ANAM) has been shown to be an accessible and promising tool for evaluating possible NPSLE in adult and childhood lupus. In this review, we present information about the development and use of Ped-ANAM; the benefit of using Ped-ANAM in children with and without NPSLE in the assessment and follow up of their disease condition; and the correlation of Ped-ANAM to imaging studies such as magnetic resonance imaging (MRI). PedANAM was validated in children with cSLE in different studies. Cognitive performance can be a challenging clinical feature to efficiently assess. However, research with the Ped-ANAM has produced a Cognitive Performance Score (CPS) that allows for a reliable and efficient estimation of cognitive ability and the presence of cognitive limitations that children with cSLE may show. Compared with traditional neurocognitive assessment tools, Ped-ANAM-CPS offers a promising alternative to overcome the difficulties that practitioners previously faced.

Published
2017

45. Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study

Author

Ndosi, Mwidimi, primary, Alcacer-Pitarch, Begonya, additional, Allanore, Yannick, additional, del Galdo, Francesco, additional, Frerix, Marc, additional, García-Díaz, Sílvia, additional, Hesselstrand, Roger, additional, Kendall, Christine, additional, Matucci-Cerinic, Marco, additional, Mueller-Ladner, Ulf, additional, Sandqvist, Gunnel, additional, Torrente-Segarra, Vicenç, additional, Schmeiser, Tim, additional, Sierakowska, Matylda, additional, Sierakowska, Justyna, additional, Sierakowski, Stanslaw, additional, and Redmond, Anthony, additional

Published
2018
Full Text
View/download PDF

46. Challenges of Diagnosing Cognitive Dysfunction With Neuropsychiatric Systemic Lupus Erythematosus in Childhood.

Author

AlE'ed, Ashwaq, Vega-Fernandez, Patricia, Muscal, Eyal, Hinze, Claas H., Tucker, Lori B., Appenzeller, Simone, Bader-Meunier, Brigitte, Roth, Johannes, Torrente-Segarra, Vicenç, Klein-Gitelman, Marisa S., Levy, Deborah M., Roebuck-Spencer, Tresa, Brunner, Hermine I., Torrente-Segarra, Vicenç, and CARRA Neuropsychiatric Systemic Lupus Erythematosus Working Group

Published
2017
Full Text
View/download PDF

48. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study

Author

Calzada Hernández, Joan, Antón López, Jordi, Bou Torrent, Rosa, Iglesias Jiménez, Estíbaliz, Ricart Campos, Sílvia, Martín de Carpi, Javier, García de Vicuña Muñoz de la Nava, Carmen, Torrente Segarra, Vicenç, Sánchez Manubens, Judith, Giménez Roca, Clara, Rozas Quesada, Librada, Juncosa Morros, Maria Teresa, Fortuny Guasch, Claudia, Noguera Julian, Antoni, and Universitat de Barcelona

Subjects
Male, medicine.medical_specialty, Tuberculosis, Adolescent, Tuberculosi, Population, Artritis reumatoide, Inflammatory bowel diseases, Adolescents, Teenagers, Inflammatory bowel disease, QuantiFERON, Anti-tumor necrosis factor-alpha drugs, Rheumatology, Latent Tuberculosis, Internal medicine, Interferon-gamma release assays, Prevalence, medicine, Humans, Immunology and Allergy, Pediatrics, Perinatology, and Child Health, Rheumatoid arthritis, Child, education, Children, Retrospective Studies, education.field_of_study, Latent tuberculosis, Tuberculin Test, Tumor Necrosis Factor-alpha, business.industry, Retrospective cohort study, Juvenile idiopathic arthritis, medicine.disease, bacterial infections and mycoses, Surgery, Malalties inflamatòries intestinals, Child, Preschool, Pediatrics, Perinatology and Child Health, Cohort, Chemoprophylaxis, Female, business, Infants, Interferon-gamma Release Tests, Research Article, Cohort study
Abstract

Background: Adult patients receiving anti-TNFα drugs are at increased risk of tuberculosis (TB), but studies in pediatric populations are limited, and the best strategy for latent tuberculosis infection (LTBI) screening in this population remains controversial. We describe the prevalence of LTBI prior to anti-TNFα therapy and the long-term follow-up after biological treatment initiation in a cohort of children and adolescents. Methods: Cohort observational study in children and adolescents receiving anti-TNFα agents in a tertiary-care pediatric hospital. LTBI was ruled out prior to the implementation of anti-TNFα drugs by tuberculin skin test (TST), and, from March 2012 on, QuantiFERON Gold-In Tube® test (QTF-G). During anti-TNFα treatment, patients were evaluated every 6 months for TB with history and physical examination. TST/QTF-G were not repeated unless signs or symptoms consistent with TB arose or there was proven TB contact. Results: The final cohort consisted of 221 patients (56.1 % female; 261 treatments), of whom 51.7 %/30.0 %/17.3 % were treated with etanercept/adalimumab/infliximab, respectively, for a variety of rheumatic diseases (75.6 %), inflammatory bowel disease (20.8 %), and inflammatory eye diseases (3.6 %). The median (IQR) age at diagnosis of the primary condition was 6.8 years (2.7-11.0) and the duration of the disease before implementing the anti-TNFα agent was 1.8 years (0.6-4.2). LTBI was diagnosed in 3 adolescent girls (prevalence rate: 1.4 %; 95 % CI: 0.4-4.2) affected with juvenile idiopathic arthritis: TST tested positive in only 1, while QTF-G was positive in all cases (including 2 patients already on etanercept). They all received antiTB chemoprophylaxis and were later (re)treated with etanercept for 24-29 months, without incidences. No incident cases of TB disease were observed during the follow-up period under anti-TNFα treatment of 641 patients-year, with a median (IQR) time per patient of 2.3 years (1.4-4.3). Conclusions: In our study, the prevalence of LTBI (1.4 %) was similar to that reported in population screening studies in Spain; no incident cases of TB disease were observed. In low-burden TB settings, initial screening for TB in children prior to anti-TNFα treatment should include both TST and an IGRA test, but systematic repetition of LTBI immunodiagnostic tests seems unnecessary in the absence of symptoms or known TB contact.

Published
2015

49. Estudio VARIAR: VAloración de la eficacia y seguridad a corto plazo en artritis reumatoide del uso de RItuximab comparado con Antagonistas del factor de necrosis tumoral alfa en segunda línea terapéutica en pacientes con artritis reumatoide Refractarios a un primer antagonista del factor de necrosis tumoral alfa

Author

Torrente-Segarra, Vicenç, primary, Acosta Pereira, Asunción, additional, Morla, Rosa, additional, Ruiz, José Miguel, additional, Clavaguera, Teresa, additional, Figuls, Ramon, additional, Corominas, Hector, additional, Geli, Carme, additional, Roselló, Rosa, additional, de Agustín, Juan José, additional, Alegre, Cayetano, additional, Pérez, Carolina, additional, García, Angel, additional, and Rodríguez de la Serna, Arturo, additional

Published
2016
Full Text
View/download PDF

50. VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist

Author

Torrente-Segarra, Vicenç, primary, Acosta Pereira, Asunción, additional, Morla, Rosa, additional, Ruiz, José Miguel, additional, Clavaguera, Teresa, additional, Figuls, Ramon, additional, Corominas, Hector, additional, Geli, Carme, additional, Roselló, Rosa, additional, de Agustín, Juan José, additional, Alegre, Cayetano, additional, Pérez, Carolina, additional, García, Angel, additional, and Rodríguez de la Serna, Arturo, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results